Table 2.
Maximum effect and EC50s of Nrf2 activator compounds on alveolar macrophage NQO1 mRNA expression and NQO1 activity
| S (n = 8) | COPD (n = 8) | |||||
|---|---|---|---|---|---|---|
| Maximum effect (fold increase) | EC50 (nM) | Maximum effect (fold increase) | EC50 (nM) | |||
| NQO1 mRNA expression | ||||||
| CDDO | 3.58†† | 19.7 | 3.39 | 11.8 | ||
| GSK compound 7 | 3.25†† | 13.1 | 2.55††† | 13.9 | ||
| C4X_6665 | 2.82†† | 1.9 | 2.61† | 1.5 | ||
| Sulforaphane | 4.12 | – | 3.41 | – | ||
| MMF | 1.53 | – | 1.62 | – | ||
| ANOVA p value | 0.0087 | – | 0.065 | |||
| NQO1 activity | ||||||
| CDDO | 2.19**$$¶¶††† | 15.3 | 2.33*$$¶¶†† | 7.3 | ||
| GSK compound 7 | 1.81† | 6.1 | 1.97¶†† | 8.9 | ||
| C4X_6665 | 1.78¶†† | 1.3 | 1.82†† | 1.2 | ||
| Sulforaphane | 1.52†† | – | 1.57††† | – | ||
| MMF | 1.07 | – | 1.25 | – | ||
| ANOVA p value | < 0.0001 | < 0.0001 | ||||
*, **Significantly above GSK7 (p < 0.05, 0.01)
$, $$Significantly above C4X_6665 (p < 0.05, 0.01)
¶, ¶¶Significantly above Sulforaphane (p < 0.05, 0.01)
†, ††, †††Significantly above MMF (p < 0.05, 0.01, 0.001)